drugset / Trial / NCT00417196

Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.

NCT00417196

Phase 1 Completed 32 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the safety, pharmacodynamic and pharmacokinetic effects of individual escalating intravenous doses of QAX576 in healthy volunteers.

Timeline

Start
2006-12
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject QAX576 Monoclonal antibody Intravenous

Indications

No indication recorded.